Certara, Inc. $CERT Stock Position Raised by Marshall Wace LLP

Marshall Wace LLP grew its position in shares of Certara, Inc. (NASDAQ:CERT) by 1,430.6% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,512,343 shares of the company’s stock after buying an additional 1,413,538 shares during the quarter. Marshall Wace LLP’s holdings in Certara were worth $17,694,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently added to or reduced their stakes in CERT. First Trust Advisors LP lifted its stake in Certara by 3,000.6% in the second quarter. First Trust Advisors LP now owns 394,924 shares of the company’s stock valued at $4,621,000 after acquiring an additional 382,187 shares during the last quarter. Invesco Ltd. raised its holdings in shares of Certara by 33.0% during the 2nd quarter. Invesco Ltd. now owns 523,965 shares of the company’s stock valued at $6,130,000 after purchasing an additional 129,928 shares in the last quarter. Claret Asset Management Corp lifted its stake in shares of Certara by 51.1% in the 2nd quarter. Claret Asset Management Corp now owns 20,437 shares of the company’s stock valued at $239,000 after purchasing an additional 6,908 shares during the last quarter. Mackenzie Financial Corp boosted its holdings in Certara by 47.7% in the second quarter. Mackenzie Financial Corp now owns 2,648,549 shares of the company’s stock worth $30,988,000 after purchasing an additional 855,222 shares in the last quarter. Finally, Tejara Capital Ltd bought a new stake in Certara in the second quarter worth $1,639,000. Institutional investors and hedge funds own 73.96% of the company’s stock.

Certara Stock Performance

Shares of NASDAQ CERT opened at $9.17 on Wednesday. Certara, Inc. has a 12 month low of $8.02 and a 12 month high of $15.69. The company has a market cap of $1.46 billion, a P/E ratio of 131.00 and a beta of 1.46. The business’s 50 day moving average is $10.70 and its two-hundred day moving average is $10.92. The company has a quick ratio of 2.09, a current ratio of 2.09 and a debt-to-equity ratio of 0.27.

Certara (NASDAQ:CERT) last posted its quarterly earnings data on Thursday, November 6th. The company reported $0.14 earnings per share for the quarter, beating the consensus estimate of $0.11 by $0.03. Certara had a return on equity of 5.18% and a net margin of 2.62%.The company had revenue of $104.62 million during the quarter, compared to analysts’ expectations of $104.53 million. During the same period in the prior year, the business earned $0.13 earnings per share. Certara has set its FY 2025 guidance at 0.450-0.470 EPS. On average, equities analysts expect that Certara, Inc. will post 0.28 EPS for the current year.

Analyst Ratings Changes

CERT has been the subject of a number of analyst reports. Wall Street Zen raised Certara from a “hold” rating to a “buy” rating in a research report on Monday, November 24th. Weiss Ratings reissued a “sell (d+)” rating on shares of Certara in a research note on Monday. Zacks Research upgraded Certara from a “strong sell” rating to a “hold” rating in a report on Friday, September 5th. Redburn Partners set a $10.00 price target on Certara in a report on Friday, November 21st. Finally, BMO Capital Markets started coverage on shares of Certara in a research report on Thursday, November 13th. They issued a “market perform” rating and a $9.00 price target on the stock. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $13.82.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.